Rigel Pharmaceuticals Launches VEPPANU as First FDA-Approved PROTAC Therapy

The commercial availability of VEPPANU (vepdegestrant) on August 13, 2026, places Rigel Pharmaceuticals at the center of a manufacturing and quality control frontier that CMC teams across the industry are watching closely: the first FDA-approved PRoteolysis TArgeting Chimera (PROTAC) introduces a bifunctional molecular architecture that sits outside the established analytical and process validation frameworks built for conventional small molecules or biologics.

Rigel reported third-quarter 2026 net product sales of $72.3 million, up 13% year-over-year, with VEPPANU contributing $6.6 million from roughly six weeks of commercial activity. Total revenues reached $80.9 million, including $8.6 million in collaboration revenues, and the company posted net income of $13.2 million. Full-year 2026 guidance was updated to $290–$295 million in total revenues, with net product sales excluding VEPPANU projected at $255–$260 million.

For QA directors and regulatory affairs leads, the PROTAC modality raises immediate questions around degrader-specific impurity profiling, linker stability under GMP storage conditions, and the adequacy of existing 21 CFR Part 211 frameworks for characterizing ternary complex formation as a quality attribute. VEPPANU is indicated for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy, as detected by an FDA-authorized companion diagnostic, adding a companion diagnostic supply-chain dependency that QA teams will need to map into their release workflows.

On the clinical pipeline side, Rigel's dual IRAK1/4 inhibitor R289 continues in a Phase 1b study in lower-risk myelodysplastic syndrome (MDS), with recommended Phase 2 dose selection expected by year-end 2026. Updated efficacy data from the dose expansion phase will be presented in an oral session at the 68th ASH Annual Meeting in December, a readout that will inform the program's CMC scale-up requirements ahead of any Phase 2 manufacturing commitments.

Internationally, Rigel's partner Knight Therapeutics secured INVIMA approval in Colombia for TAVALISSE (fostamatinib) in chronic immune thrombocytopenia and commercially launched the product in Brazil in October, extending the supply network obligations Rigel carries under that collaboration.

The pace of VEPPANU refill activity in the first six weeks of launch will serve as an early indicator of whether the commercial manufacturing batch cadence is calibrated to real-world demand.

Source: Rigel Pharmaceuticals, Inc. press release via PR Newswire, November 5, 2026. Conference call and webcast scheduled at 4:30 p.m. Eastern Time on the same date.